QLC7401 not checked
Qilu Pharmaceutical · RBD7022
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “QLC7401 is a small interfering RNA (siRNA) targeting PCSK9. Administered as subcutaneous injection at a specified dose level.”In the company’s words, NCT07450378 on ClinicalTrials.gov
- Tested for
- Primary Hypercholesterolemia or Mixed Hyperlipidemia (3 trials), Heterozygous Familial Hypercholesterolemia (HeFH), Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C
- Main trialPhase 3
- “This Phase III clinical trial aims to assess the efficacy and safety of QLC7401 monotherapy in adults with non-familial primary hypercholesterolemia or mixed dyslipidemia who are not receiving lipid-lowering therapy. Participants will be randomly assigned to receive subcutaneous injections of either QLC7401 or a placebo according to the study schedule.”In the company’s words, NCT07444086 on ClinicalTrials.gov
- Other names
- RBD7022
Other drugs for Primary Hypercholesterolemia or Mixed Hyperlipidemia
Coming up3
- 7 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- Apr 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 7 Oct 2027 | QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia | |
| Phase 3Not yet recruiting | Dec 2027 | QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) | |
| Phase 3Not yet recruiting | Apr 2028 | QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) | |
| Phase 2Not yet recruiting | Jun 2026 | Study of QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated LDL Cholesterol | |
| Phase 1Not yet recruiting | Jan 2026 | Pharmacokinetics and Pharmacodynamics Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026